{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:46:10Z","timestamp":1792089970123,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To explore the real-world uptake and engagement with OpenSYMPRO, a digital symptom-monitoring tool for patients with cancer undergoing systemic therapy, and potential barriers to its use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The original study aimed to compare adolescents and young adults (AYAs) using openly accessible OpenSYMPRO with patients aged\u2009&gt;\u200940\u00a0years using hospital-based regular SYMPRO. OpenSYMPRO was also accessible to older patients. Due to low recruitment, the planned comparative evaluation was abandoned. Engagement was summarized descriptively. All 20 enrolled participants were invited to provide feedback, and all available interviews and questionnaires were analyzed thematically, irrespective of age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 20 enrolled participants, 18 registered through OpenSYMPRO and 2 through regular SYMPRO. Seven completed\u2009&gt;\u20092 symptom questionnaires, 9 completed 1\u20132, and 4 completed none. Nine participants provided qualitative feedback through interviews (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094) or questionnaires (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095), including 7 AYAs and 2 participants outside the AYA age range. Potential barriers included concurrent studies, perceived overlap between studies, forgetting the tool, limited time or cognitive capacity, and limited perceived added value. Some participants found symptom tracking useful. Respondents reported no substantial problems with technical operation, although design-related barriers could not be excluded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Uptake and engagement appeared to be influenced primarily by organizational, communication, and personal factors rather than technical operation. Stronger integration into clinical workflows, person-tailored communication of purpose and added value, active healthcare professional involvement, and attention to potential design barriers warrant further evaluation. Given the small and heterogeneous sample, and limited feedback from non-users and non-participants, findings are hypothesis-generating.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-11297-3","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:28:16Z","timestamp":1790929696000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Digital symptom monitoring in cancer care: an exploratory evaluation of low uptake and engagement"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0818-2913","authenticated-orcid":false,"given":"Floortje","family":"Mols","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Bol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Sleeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Husson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mies","family":"van Eenbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"van den Hurk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"issue":"3","key":"11297_CR1","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.soncn.2015.05.003","volume":"31","author":"AJ Bukowinski","year":"2015","unstructured":"Bukowinski AJ et al (2015) Toxicity of cancer therapy in adolescents and young adults (AYAs). Semin Oncol Nurs 31(3):216\u2013226","journal-title":"Semin Oncol Nurs"},{"issue":"10 Suppl","key":"11297_CR2","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1002\/cncr.26056","volume":"117","author":"BJ Zebrack","year":"2011","unstructured":"Zebrack BJ (2011) Psychological, social, and behavioral issues for young adults with cancer. Cancer 117(10 Suppl):2289\u20132294","journal-title":"Cancer"},{"issue":"23","key":"11297_CR3","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1093\/jnci\/djp386","volume":"101","author":"E Basch","year":"2009","unstructured":"Basch E et al (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. JNCI J Natl Cancer Inst 101(23):1624\u20131632","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"7","key":"11297_CR4","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s11136-011-0031-4","volume":"21","author":"TM Atkinson","year":"2012","unstructured":"Atkinson TM et al (2012) Reliability of adverse symptom event reporting by clinicians. Qual Life Res 21(7):1159\u20131164","journal-title":"Qual Life Res"},{"key":"11297_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3564","author":"A Ooki","year":"2020","unstructured":"Ooki A et al (2020) Disagreement between patient\u2010and physician\u2010reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first\u2010line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial. Cancer Med. https:\/\/doi.org\/10.1002\/cam4.3564","journal-title":"Cancer Med"},{"issue":"32","key":"11297_CR6","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1200\/JCO.2007.12.4784","volume":"25","author":"A Trotti","year":"2007","unstructured":"Trotti A et al (2007) Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 25(32):5121\u20135127","journal-title":"J Clin Oncol"},{"issue":"6","key":"11297_CR7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","volume":"34","author":"E Basch","year":"2016","unstructured":"Basch E et al (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557","journal-title":"J Clin Oncol"},{"issue":"5","key":"11297_CR8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S1470-2045(18)30141-4","volume":"19","author":"E Basch","year":"2018","unstructured":"Basch E (2018) Patient-reported outcomes: an essential component of oncology drug development and regulatory review. Lancet Oncol 19(5):595\u2013597","journal-title":"Lancet Oncol"},{"issue":"34","key":"11297_CR9","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1200\/JCO.2007.11.2243","volume":"25","author":"E Basch","year":"2007","unstructured":"Basch E et al (2007) Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol 25(34):5374\u20135380","journal-title":"J Clin Oncol"},{"issue":"16","key":"11297_CR10","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1200\/JCO.2012.45.8117","volume":"31","author":"MC Pietanza","year":"2013","unstructured":"Pietanza MC et al (2013) Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial. J Clin Oncol 31(16):2004\u20132009","journal-title":"J Clin Oncol"},{"issue":"5","key":"11297_CR11","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/COC.0000000000000189","volume":"40","author":"F Denis","year":"2017","unstructured":"Denis F et al (2017) Improving survival in patients treated for a lung cancer using self-evaluated symptoms reported through a web application. Am J Clin Oncol 40(5):464\u2013469","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"11297_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jama.2017.7156","volume":"318","author":"E Basch","year":"2017","unstructured":"Basch E et al (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318(2):197\u2013198","journal-title":"JAMA"},{"issue":"3","key":"11297_CR13","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/jama.2018.18085","volume":"321","author":"F Denis","year":"2019","unstructured":"Denis F et al (2019) Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer. JAMA 321(3):306\u2013307","journal-title":"JAMA"},{"key":"11297_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1647","volume":"374","author":"R Maguire","year":"2021","unstructured":"Maguire R et al (2021) Real time remote symptom monitoring during chemotherapy for cancer: European multicentre randomised controlled trial (eSMART). BMJ 374:n1647","journal-title":"BMJ"},{"issue":"4","key":"11297_CR15","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41591-025-03507-y","volume":"31","author":"E Basch","year":"2025","unstructured":"Basch E et al (2025) Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial. Nat Med 31(4):1225\u20131232","journal-title":"Nat Med"},{"issue":"7","key":"11297_CR16","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1200\/JCO.20.02015","volume":"39","author":"K Absolom","year":"2021","unstructured":"Absolom K et al (2021) Phase III randomized controlled trial of eRAPID: eHealth intervention during chemotherapy. J Clin Oncol 39(7):734\u2013747","journal-title":"J Clin Oncol"},{"issue":"8","key":"11297_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.28975","volume":"7","author":"NE Billingy","year":"2024","unstructured":"Billingy NE et al (2024) Patient- vs physician-initiated response to symptom monitoring and health-related quality of life: the SYMPRO-Lung cluster randomized trial. JAMA Netw Open 7(8):e2428975","journal-title":"JAMA Netw Open"},{"issue":"6","key":"11297_CR18","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.3390\/curroncol29060349","volume":"29","author":"CJG van den Hurk","year":"2022","unstructured":"van den Hurk CJG et al (2022) A narrative review on the collection and use of electronic patient-reported outcomes in cancer survivorship care with emphasis on symptom monitoring. Curr Oncol 29(6):4370\u20134385","journal-title":"Curr Oncol"},{"issue":"9","key":"11297_CR19","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1007\/s00520-019-4639-1","volume":"27","author":"MC van Eenbergen","year":"2019","unstructured":"van Eenbergen MC et al (2019) Usability of an online application for reporting the burden of side effects in cancer patients. Support Care Cancer 27(9):3411\u20133419","journal-title":"Support Care Cancer"},{"key":"11297_CR20","doi-asserted-by":"publisher","unstructured":"Billingy NE, Tromp VNMF, Veldhuijzen E, Belderbos J, Aaronson NK, Feldman E, Hoek R, Bogaard HJ, Onwuteaka-Philipsen BD, van de Poll-Franse L, Hugtenburg JG, van den Hurk CJG, Becker-Commissaris A, Walraven I (2021) SYMptom monitoring with Patient-Reported Outcomes using a web application among patients with Lung cancer in the Netherlands (SYMPRO-Lung): study protocol for a stepped-wedge randomised controlled trial. BMJ Open 11(9):e052494. https:\/\/doi.org\/10.1136\/bmjopen-2021-052494","DOI":"10.1136\/bmjopen-2021-052494"},{"issue":"1","key":"11297_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11094-9","volume":"23","author":"H Yildirim","year":"2023","unstructured":"Yildirim H et al (2023) The PRO-RCC study: a long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for \u201cTrial within Cohorts\u201d study designs. BMC Cancer 23(1):648","journal-title":"BMC Cancer"},{"key":"11297_CR22","unstructured":"IKNl. About Profiles Registry. [cited 2020; Available from: https:\/\/www.profilesregistry.nl\/about-profiles-registry\/."},{"issue":"9","key":"11297_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052494","volume":"11","author":"NE Billingy","year":"2021","unstructured":"Billingy NE et al (2021) Symptom monitoring with patient-reported outcomes using a web application among patients with lung cancer in the Netherlands (SYMPRO-Lung): study protocol for a stepped-wedge randomised controlled trial. BMJ Open 11(9):e052494","journal-title":"BMJ Open"},{"key":"11297_CR24","doi-asserted-by":"publisher","unstructured":"Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D (2014) Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 106(9):dju244. https:\/\/doi.org\/10.1093\/jnci\/dju244","DOI":"10.1093\/jnci\/dju244"},{"issue":"8","key":"11297_CR25","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","volume":"1","author":"AC Dueck","year":"2015","unstructured":"Dueck AC et al (2015) Validity and reliability of the US National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol 1(8):1051\u20131059","journal-title":"JAMA Oncol"},{"issue":"1","key":"11297_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41687-020-00249-y","volume":"4","author":"E Veldhuijzen","year":"2020","unstructured":"Veldhuijzen E et al (2020) Dutch translation and linguistic validation of the US National Cancer Institute\u2019s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE\u2122). J Patient Rep Outcomes 4(1):1\u201311","journal-title":"J Patient Rep Outcomes"},{"key":"11297_CR27","doi-asserted-by":"publisher","unstructured":"Basch E, Becker C, Rogak LJ, Schrag D, Reeve BB, Spears P, Smith ML, Gounder MM, Mahoney MR, Schwartz GK, Bennett AV, Mendoza TR, Cleeland CS, Sloan JA, Bruner DW, Schwab G, Atkinson TM, Thanarajasingam G, Bertagnolli MM, Dueck AC (2020) Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Clin Trials 18(1):104-114. https:\/\/doi.org\/10.1177\/1740774520975120","DOI":"10.1177\/1740774520975120"},{"issue":"1","key":"11297_CR28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12955-018-0920-0","volume":"16","author":"M van Leeuwen","year":"2018","unstructured":"van Leeuwen M et al (2018) Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire. Health Qual Life Outcomes 16(1):114","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"11297_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s41687-020-00212-x","volume":"4","author":"D Howell","year":"2020","unstructured":"Howell D et al (2020) Personalized symptom management: a quality improvement collaborative for implementation of patient reported outcomes (PROs) in \u201creal-world\u201d oncology multisite practices. J Patient Rep Outcomes 4(1):47","journal-title":"J Patient Rep Outcomes"},{"issue":"6","key":"11297_CR30","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.pec.2015.12.010","volume":"99","author":"S Perri-Moore","year":"2016","unstructured":"Perri-Moore S et al (2016) Automated alerts and reminders targeting patients: a review of the literature. Patient Educ Couns 99(6):953\u2013959","journal-title":"Patient Educ Couns"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11297-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11297-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11297-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:48:18Z","timestamp":1792086498000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11297-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["11297"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11297-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Patients interested in OpenSYMPRO could register via email and immediately access the app after providing digital informed consent. App use was linked to participation in this study, which was reviewed by an official medical ethics committee (METC Brabant, the Netherlands) and declared exempt from the Medical Research Involving Human Subjects Act (non-WMO declaration, NW2021-76). This study was performed in compliance with the Declaration of Helsinki. Data collection complied with GDPR regulations. Participants were informed about data use before consenting and could withdraw from the study at any time without consequences.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1045"}}